Maraş Otunun Ağrı Şiddeti, Ağrı Eşiği ve Ağrı Toleransı Üzerine Etkisi

Amaç: Bu çalışma, dumansız bir tütün formu olan maraş otunun kronik kullanımının ağrı şiddeti, ağrı eşiği ve ağrı toleransı üzerine herhangi bir etkisinin olup olmadığını belirlemek amacı ile planlanmıştır. Yöntemler: Çalışmaya herhangi bir hastalığı bulunmayan 18-39 yaş arası, en az 5 yıldır maraş otu kullanan 10 kişi ve maraş otu ya da herhangi bir tütün ürünü kullanmayan 10 kişi olmak üzere toplam 20 sağlıklı erkek dahil edildi. Maraş otu kullanan kişilere deneylerden en az 12 saat önce maraş otu kullanmamaları söylendi. Maraş otu kullanan ve kullanmayan kişilerin ağrı şiddetleri, ağrı eşikleri ve ağrı toleransları karşılaştırıldı. Ağrı şiddeti vizüel analog skala (VAS) ile değerlendirildi. Ağrı eşiği ve ağrı toleransı soğuk pressör testi ile ölçüldü. Çalışmanın sonuçları Mann-Whitney U testi kullanılarak analiz edildi. Bulgular: Maraş otu kullanan kişilerde ağrı eşiği 17,11±4,59, ağrı toleransı 47,82±16,27 ve VAS 5,78±0,83; Maraş otu ya da herhangi bir tütün ürünü kullanmayan kişilerde ise ağrı eşiği 21,79±6,11, ağrı toleransı 72,82±22,36 ve VAS 3,78±0,97 olarak tespit edildi. Maraş otu kullanan kişilerin kullanmayanlara göre ağrı şiddeti (VAS) anlamlı olarak yüksek bulunurken (p=0,001); ağrı eşiği ve ağrı toleransı anlamlı olarak düşük bulundu (p=0,016, p=0,012; sırasıyla). Sonuç: Bu çalışmadan elde edilen sonuçlar kronik maraş otu kullanan kişilerin kullanmayanlara göre hissettikleri ağrı şiddetinin daha yüksek olduğunu, ağrı eşiği ve ağrı toleranslarının ise daha düşük olduğunu göstermiştir. Dumansız tütün ürünlerinin ağrı üzerine etkilerini araştıran daha fazla çalışmaya ihtiyaç vardır.

The Effect of Maras Powder on Pain Intensity, Pain Threshold, and Pain Tolerance

Objective: This study was planned to determine whether the chronic use of maras powder, a smokeless form of tobacco, has any effect on pain intensity, pain threshold, and pain tolerance. Methods: A total of 20 healthy males without any illness and aged between 18-39 years were included in the study, including 10 people who had been using maras powder for at least 5 years, and 10 who had not used maras powder or any tobacco product. People using maras powder were told not to use maras powder at least 12 hours before the experiments. The pain intensity, pain thresholds, and pain tolerance of the people who used and did not use maras powder were compared. Pain intensity was evaluated with the visual analog scale (VAS). Pain threshold and pain tolerance were measured by the cold pressor test. The results of the study were analyzed using the Mann-Whitney U test. Results: Pain threshold was 17.11 ± 4.59, pain tolerance was 47.82 ± 16.27 and VAS was 5.78 ± 0.83 in individuals using maras powder; Pain threshold was found as 21.79 ± 6.11, pain tolerance as 72.82 ± 22.36 and VAS 3.78 ± 0.97 in individuals who did not use maras powder or any tobacco product. While pain intensity (VAS) of people using maras powder was significantly higher than those who did not use it (p=0.001); their pain threshold and pain tolerance were found to be significantly lower than those who did not use it (p=0.016, p=0.012; respectively). Conclusion: The results obtained from this study showed that the pain intensity they felt of the people using chronically maras powder was higher than those who did not use it, and their pain threshold and pain tolerance were lower than those who did not use it. More studies are needed to investigate the effects of smokeless tobacco products on pain.

PDF

___

1.Köse E, Yazıcıoğlu Moçin Ö, Çelik H, Gencer M.Dumansız Tütün “Maraş Otu” Kullanımına BağlıArtmış Oksidatif Stres. Tur Toraks Der. 2011; 12: 94-9.
2.Saitoh F, Noma M, Kawashima N. The alkaloidcontents of sixty nicotine species. Phytochemistry.1985; 24: 477–80.
3.Merskey H, Bogduk N. Classification of chronicpain. 2nd edn. Seattle: IASP Press; 1994: 207-13.
4.Tütüncü R, Günay H. Chronic pain, psychologicalfactors and depression. Dicle Med J. 2011; 38: 257-62.
5.Nastase A, Ioan S, Braga RI, Zagrean L, MoldovanM.Coffee drinking enhances the analgesic effect ofcigarette smoking. Neuroreport. 2007; 18: 921-4.
6.Bagot KS, Wu R, Cavallo D, Krishnan-Sarin S.Assessment of pain in adolescents: Influence ofgender, smoking status and tobacco abstinence.Addict Behav. 2017; 67: 79-85.
7.Zhang Y, Yang J, Sevilla A, et al. The mechanism ofchronic nicotine exposure and nicotine withdrawalon pain perception in an animal model. NeurosciLett. 2020; 715: 134627.
8.Aceto MD, Awaya H, Martin BR, May EL.Antinociceptive action of nicotine and itsmethiodide derivatives in mice and rats. Br JPharmacol. 1983; 79: 869–76.
9.Phan DV, Dóda M, Bite A, György L.Antinociceptive activity of nicotine. Acta PhysiolAcad Sci Hung. 1973; 44: 85–93.
10.Waller D, Schalling D, Levander S, Edman G.Smoking, pain tolerance, and physiologicalactivation. Psychopharmacology (Berl). 1983; 79:193–8.
11.Kanarek RB, Carrington C. Sucrose consumptionenhances the analgesic effects of cigarette smokingin male and female smokers. Psychopharmacology(Berl). 2004; 173: 57–63.
12.Tripathi HL, Martin BR, Aceto MD. Nicotine-induced antinociception in rats and mice:Correlation with nicotine brain levels. J PharmacolExp Ther. 1982; 221: 91–6.
13.Marubio LM, del Mar Arroyo-Jimenez M,Cordero-Erausquin M, et al. Reducedantinociception in mice lacking neuronal nicotinicreceptor subunits. Nature. 1999; 398: 805-10.
14.Rao TS, Correa LD, Reid RT, Lloyd GK. Evaluationof anti-nociceptive effects of neuronal nicotinicacetylcholine receptor (NAChR) ligands in the rattail-flick assay. Neuropharmacology. 1996; 35: 393–405.
15.Andersson H, Ejlertsson G, Leden I. Widespreadmusculoskeletal chronic pain associated withsmoking. An epidemiological study in a general ruralpopulation. Scand J Rehabil Med. 1998; 30: 185–91.
16.Weingarten TN, Iverson BC, Shi Y, et al. Impact oftobacco use on the symptoms of painfultemporomandibular joint disorders. Pain. 2009; 147: 67-71.
17. Weingarten TN, Podduturu VR, Hooten WM, et al.Impact of tobacco use in patients presenting to amultidisciplinary outpatient treatment program forfibromyalgia. Clin J Pain. 2009; 25: 39-43.
18.Weingarten TN, Moeschler SM, Ptaszynski AE, etal. An assessment of the association betweensmoking status, pain intensity, and functionalinterference in patients with chronic pain. PainPhysician. 2008; 11: 643–53.
19.Kim DH, Park JY, Karm MH, et al. Smoking MayIncrease Postoperative Opioid Consumption inPatients Who Underwent Distal Gastrectomy WithGastroduodenostomy for Early Stomach Cancer: ARetrospective Analysis. Clin J Pain. 2017; 33: 905-11.
20.Ditre JW, Heckman BW, Zale EL, Kosiba JD,Maisto SA. Acute analgesic effects of nicotine andtobacco in humans: a meta-analysis. Pain. 2016; 157:1373-81.
21.Ditre JW, Brandon TH, Zale EL, Meagher MM.Pain, nicotine, and smoking: Research findings andmechanistic considerations. Psychol Bull. 2011; 137:1065–93.
22.Shi Y, Weingarten TN, Mantilla CB, Hooten WM,Warner DO. Smoking and pain: Pathophysiology andclinical implications. Anesthesiology. 2010; 113:977–92.